Contineum Therapeutics, Inc. - Common stock (CTNM)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- P/B of 1.27 — trading near book value
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -23.7%
- Revenue declining 100% annually
Contineum Therapeutics, Inc. - Common stock (CTNM) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $316 million . Key value metrics: P/B ratio 1.27, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Revenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Contineum Therapeutics, Inc. - Common stock — Fundamental Analysis Summary
On financial health, CTNM shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -23.7% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.06.
StockPik's composite Value Score for CTNM is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CTNM shows revenue declining at 100% year-over-year, with earnings declining at 42%.